Macrogenics Inc
A biotech company that engineers antibody-based therapies to fight cancer. Its drug MARGENZA was approved in 2020 for HER2-positive breast cancer, and its DART platform builds proteins that bind two targets at once, steering immune cells toward tumors. Founded in 2000 in Rockville, Maryland, by a team of scientists, its name combines "macro," for the large protein molecules it builds, with "genics," echoing genetic engineering.
Bought 350.0K
Granted 206.2K
Granted 71.3K · Sold 30.0K
Granted 107.5K · Sold 48.8K
Granted 14.8K · Bought 100.0K
Granted 94.0K · Sold 41.2K
Granted 14.8K · Bought 15.0K
Granted 74.0K · Sold 10.0K
Granted 228.6K · Sold 163.4K
Granted 44.5K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 8.0K · Sold 423
Granted 6.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| BB Biotech Ag +1 co-filer10% owner · 2 transactions | +3.7% | 9.93Mas of Oct 2023 | — | 350.0K | — |
| Koenig ScottDirector · 12 transactions | -17.4% | 867.2K | 206.2K | — | — |
| Karrels JamesSVP and CFO · 13 transactions | +7.4% | 206.0K | 71.3K | — | 30.0K |
| Bonvini EzioSr VP, Research & CSO · 17 transactions | +17.8% | 145.8K | 107.5K | — | 48.8K |
| Heiden William KDirector · 5 transactions | — | 114.8K | 14.8K | 100.0K | — |
| Risser Eric BlasiusPresident and CEO, Director · 15 transactions | +44.3% | 77.2K | 94.0K | — | 41.2K |
| Hurwitz EdwardDirector · 4 transactions | +164.6% | 47.8K | 14.8K | 15.0K | — |
| Spitznagel ThomasSr VP, Technical Ops · 14 transactions | +670.9% | 38.5K | 74.0K | — | 10.0K |
| Peters Jeffrey StuartSenior VP, GC, and Secretary · 28 transactions | — | 31.1K | 228.6K | — | 163.4K |
| Eck Stephen L.Chief Medical Officer · 6 transactions | — | 29.4Kas of Feb 2025 | 44.5K | — | — |
| Chhabra MeenuDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Ferrante Karen JeanDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Jackson Scott ThomasDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Liu MargaretDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| O'Brien Federica F.Director · 3 transactions | — | 14.8K | 14.8K | — | — |
| Siegel Jay PhilipDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Stump David CDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Smith Beth AnnVP, Controller & Treasurer · 10 transactions | — | 13.2K | 8.0K | — | 423 |
| Cilinski LynnVP, Controller and Treasurer · 2 transactions | -37.3% | 6.2Kas of Feb 2024 | 6.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +171.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.